4G7-CAR scFV for Prolonged T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chimeric antigen receptors (CARs) for treating B-cell lymphomas and leukemia, such as those targeting CD19, face challenges in achieving prolonged T-cell proliferation and clinical effectiveness due to limited compatibility with T-cell activation mechanisms.
Innovation Solution
Development of a CD19-specific chimeric antigen receptor (4G7-CAR) with a scFV derived from the CD19 monoclonal antibody 4G7, which confers a prolonged 'activated' state to transduced T cells independently of antigen binding, enhancing antigen-independent activation and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CARs targeting CD19 are used, then T-cell specificity against B-cell lymphomas and leukemia is achieved, but T-cell proliferation and clinical effectiveness are limited
Solution Approach 1:
The patent changes the scFV sequence parameters by using 4G7-derived scFV instead of conventional FMC63 scFV, which alters the CAR's signaling properties to achieve prolonged T-cell activation and proliferation independent of continuous antigen binding
Solution Approach 2:
The 4G7-CAR maintains continuous T-cell activation and proliferation signals over extended periods without requiring continuous antigen stimulation, enabling sustained clinical effectiveness through prolonged 'activated' state
2Measurement precision
If CARs are designed to bind CD19 antigen, then tumor specificity is improved, but compatibility with T-cell activation mechanisms is reduced
Solution Approach 1:
The patent modifies the CAR's scFV parameters (using 4G7-derived sequences) to change its signaling characteristics, making it compatible with natural T-cell activation mechanisms while maintaining CD19 specificity
Solution Approach 2:
The 4G7-CAR system serves itself by generating sustained activation signals that automatically maintain T-cell proliferation and effectiveness without external intervention or continuous antigen presence
Data Source
AI summary
The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.